{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:05:01Z","timestamp":1789790701701,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sunitinib, a multitargeted tyrosine kinase inhibitor, is used in advanced clear cell renal cell carcinoma (ccRCC). Corrected QT interval (QTc) prolongation is a recognized cardiovascular toxicity of this therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the incidence, timing, and severity of QTc prolongation in real-world advanced ccRCC patients treated with first-line sunitinib, compare Bazett\u2019s and Fridericia\u2019s correction formulas, and identify risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective single-center cohort study included 67 patients between January 2019 and June 2022. QTc was calculated manually using Bazett\u2019s and Fridericia\u2019s formulas and graded per Common Terminology Criteria for Adverse Events (CTCAE) v5.0. The incidence, timing, and severity of QTc prolongation were assessed based on the highest recorded QTc value. Statistical analyses compared QTc values between formulas and evaluated potential clinical predictors of QTc prolongation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median treatment duration was 1.4 years (IQR 0.72\u20132.99). QTc prolongation \u2265\u2009450ms occurred in 44.8% of patients (Bazett) and 34.3% (Fridericia) and \u2265\u2009500ms in 7 and 6 patients, respectively. The median onset of QTc \u2265\u2009450ms was cycle 7.9 (Bazett) and 10.4 (Fridericia). Bazett\u2019s values were significantly higher across most treatment cycles (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Older age, thyroid dysfunction, smoking history, hypertension and soft-tissue metastases were associated with increased risk of QTc prolongation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>QTc prolongation was frequent and occurred both early and later during therapy. Fridericia\u2019s formula provided more accurate and stable values and should be preferred for monitoring. Repeated ECG measurements and close cardio-oncology collaboration are essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00280-026-04884-y","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:31:58Z","timestamp":1777433518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of QTc interval prolongation in patients with advanced clear cell renal cell carcinoma treated with first line sunitinib"],"prefix":"10.1007","volume":"96","author":[{"given":"Agata","family":"Sa\u0142ek-Za\u0144","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miros\u0142awa","family":"P\u00fcsk\u00fcll\u00fco\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"St\u0105p\u00f3r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Jaworska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Pietruszka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Grela-Wojewoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"St\u0105p\u00f3r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Bana\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"4884_CR1","unstructured":"Motzer RJMSKCC\u00deJEANBHBM et al (2025) NCCN Guidelines Version 1.2026 \u2014 July 24, 2025, Kidney Cancer [Internet]. 2025. In: NCCN Guidelines Version 1.2026. Available from: https:\/\/www.nccn.org\/home\/"},{"key":"4884_CR2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Albiges L, Bex A et al (2024) Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 35:692\u2013706. https:\/\/doi.org\/10.1016\/j.annonc.2024.05.537","journal-title":"Ann Oncol"},{"key":"4884_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN et al (2025) Cancer statistics, 2025. CA Cancer J Clin 75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"key":"4884_CR4","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","volume":"35","author":"NM Tannir","year":"2024","unstructured":"Tannir NM, Albig\u00e8s L, McDermott DF et al (2024) Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol 35:1026\u20131038. https:\/\/doi.org\/10.1016\/j.annonc.2024.07.727","journal-title":"Ann Oncol"},{"key":"4884_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","volume":"84","author":"ER Plimack","year":"2023","unstructured":"Plimack ER, Powles T, Stus V et al (2023) Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study. Eur Urol 84:449\u2013454. https:\/\/doi.org\/10.1016\/j.eururo.2023.06.006","journal-title":"Eur Urol"},{"key":"4884_CR6","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.23.01569","volume":"42","author":"RJ Motzer","year":"2024","unstructured":"Motzer RJ, Porta C, Eto M et al (2024) Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. J Clin Oncol 42:1222\u20131228. https:\/\/doi.org\/10.1200\/JCO.23.01569","journal-title":"J Clin Oncol"},{"key":"4884_CR7","doi-asserted-by":"publisher","first-page":"7754","DOI":"10.1038\/s41598-019-44226-y","volume":"9","author":"AM Czarnecka","year":"2019","unstructured":"Czarnecka AM, Brodziak A, Sobczuk P et al (2019) Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma. Sci Rep 9:7754. https:\/\/doi.org\/10.1038\/s41598-019-44226-y","journal-title":"Sci Rep"},{"key":"4884_CR8","doi-asserted-by":"publisher","unstructured":"Vandenberk B, Vandael E, Robyns T et al (2016) Which QT Correction Formulae to Use for QT Monitoring? J Am Heart Assoc 5. https:\/\/doi.org\/10.1161\/JAHA.116.003264","DOI":"10.1161\/JAHA.116.003264"},{"key":"4884_CR9","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1001\/jamaoncol.2022.4194","volume":"8","author":"DR Richardson","year":"2022","unstructured":"Richardson DR, Parish PC, Tan X et al (2022) Association of QTc Formula With the Clinical Management of Patients With Cancer. JAMA Oncol 8:1616. https:\/\/doi.org\/10.1001\/jamaoncol.2022.4194","journal-title":"JAMA Oncol"},{"key":"4884_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/bjc.2015.82","volume":"112","author":"JSL Kloth","year":"2015","unstructured":"Kloth JSL, Pagani A, Verboom MC et al (2015) Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer 112:1011\u20131016. https:\/\/doi.org\/10.1038\/bjc.2015.82","journal-title":"Br J Cancer"},{"key":"4884_CR11","doi-asserted-by":"publisher","first-page":"7045","DOI":"10.1158\/1078-0432.CCR-09-1521","volume":"15","author":"CL Bello","year":"2009","unstructured":"Bello CL, Mulay M, Huang X et al (2009) Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib. Clin Cancer Res 15:7045\u20137052. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1521","journal-title":"Clin Cancer Res"},{"key":"4884_CR12","doi-asserted-by":"publisher","unstructured":"Porta-S\u00e1nchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, Thavendiranathan P. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017 Dec 7;6(12):e007724. https:\/\/doi.org\/10.1161\/JAHA.117.007724","DOI":"10.1161\/JAHA.117.007724"},{"key":"4884_CR13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46009","author":"B Lima","year":"2023","unstructured":"Lima B, Razmjouei S, Bajwa MT et al (2023) Polypharmacy, Gender Disparities, and Ethnic and Racial Predispositions in Long QT Syndrome: An In-Depth Review. Cureus https:\/\/doi.org\/10.7759\/cureus.46009","journal-title":"Cureus"},{"key":"4884_CR14","doi-asserted-by":"publisher","unstructured":"Li D, Chai S, Wang H et al (2023) Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database. Front Pharmacol 14. https:\/\/doi.org\/10.3389\/fphar.2023.1259611","DOI":"10.3389\/fphar.2023.1259611"},{"key":"4884_CR15","doi-asserted-by":"publisher","first-page":"152027","DOI":"10.1016\/j.bbrc.2025.152027","volume":"771","author":"M Gao","year":"2025","unstructured":"Gao M, Cheng Z, Yan W et al (2025) Tyrosine kinase inhibitors induce cardiotoxicity by causing Ca2\u2009+\u2009overload through the inhibition of phosphoinositide 3-kinase activity. Biochem Biophys Res Commun 771:152027. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152027","journal-title":"Biochem Biophys Res Commun"},{"key":"4884_CR16","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1200\/JCO.19.00922","volume":"37","author":"B Muluneh","year":"2019","unstructured":"Muluneh B, Richardson DR, Hicks C et al (2019) Trials and Tribulations of Corrected QT Interval Monitoring in Oncology: Rationale for a Practice-Changing Standardized Approach. J Clin Oncol 37:2719\u20132721. https:\/\/doi.org\/10.1200\/JCO.19.00922","journal-title":"J Clin Oncol"},{"key":"4884_CR17","doi-asserted-by":"publisher","unstructured":"Grela-Wojewoda A, Pacholczak-Madej R, Adamczyk A, Korman M, P\u00fcsk\u00fcll\u00fco\u011flu M. Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. Int J Mol Sci. 2022 Mar 4;23(5):2815. https:\/\/doi.org\/10.3390\/ijms23052815","DOI":"10.3390\/ijms23052815"},{"key":"4884_CR18","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1177\/2047487318755193","volume":"25","author":"M Totzeck","year":"2018","unstructured":"Totzeck M, Mincu R-I, Mrotzek S et al (2018) Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol 25:482\u2013494. https:\/\/doi.org\/10.1177\/2047487318755193","journal-title":"Eur J Prev Cardiol"},{"key":"4884_CR19","unstructured":"Sunitinib, Summary of Product Characteristics. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20161109136193\/anx_136193_pl.pdf"},{"key":"4884_CR20","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W","volume":"53","author":"V Mor","year":"1984","unstructured":"Mor V, Laliberte L, Morris JN, Wiemann M (1984) The Karnofsky performance status scale: An examination of its reliability and validity in a research setting. Cancer 53:2002\u20132007. https:\/\/doi.org\/10.1002\/1097-0142(19840501)53:9%3C2002::aid-cncr2820530933%3E3.0.co;2-w","journal-title":"Cancer"},{"key":"4884_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","volume":"14","author":"DYC Heng","year":"2013","unstructured":"Heng DYC, Xie W, Regan MM et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14:141\u2013148. https:\/\/doi.org\/10.1016\/S1470-2045(12)70559-4","journal-title":"Lancet Oncol"},{"key":"4884_CR22","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1200\/JCO.2002.11.123","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer RJ, Bacik J, Mariani T et al (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20:2376\u20132381. https:\/\/doi.org\/10.1200\/JCO.2002.11.123","journal-title":"J Clin Oncol"},{"key":"4884_CR23","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV et al (2024) 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 45:3314\u20133414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176","journal-title":"Eur Heart J"},{"key":"4884_CR24","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43:4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"key":"4884_CR25","unstructured":"https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events"},{"key":"4884_CR26","unstructured":"R Core Team (2024) R: A language and environment for statistical computing. In: R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/"},{"key":"4884_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11886-023-01845-2","volume":"25","author":"N Sayegh","year":"2023","unstructured":"Sayegh N, Yirerong J, Agarwal N et al (2023) Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors. Curr Cardiol Rep 25:269\u2013280. https:\/\/doi.org\/10.1007\/s11886-023-01845-2","journal-title":"Curr Cardiol Rep"},{"key":"4884_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaccao.2021.01.002","volume":"3","author":"PY Kim","year":"2021","unstructured":"Kim PY, Irizarry-Caro JA, Ramesh T et al (2021) How to Diagnose and Manage QT Prolongation in Cancer Patients. JACC CardioOncol 3:145\u2013149. https:\/\/doi.org\/10.1016\/j.jaccao.2021.01.002","journal-title":"JACC CardioOncol"},{"key":"4884_CR29","volume-title":"SUTENT (sunitinib malate) prescribing information","author":"Pfizer Inc","year":"2021","unstructured":"Pfizer Inc (2021) SUTENT (sunitinib malate) prescribing information. Pfizer Inc., New York"},{"key":"4884_CR30","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/bjc.2014.564","volume":"112","author":"P Ghatalia","year":"2015","unstructured":"Ghatalia P, Je Y, Kaymakcalan MD et al (2015) QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 112:296\u2013305. https:\/\/doi.org\/10.1038\/bjc.2014.564","journal-title":"Br J Cancer"},{"key":"4884_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13063-018-2613-8","volume":"19","author":"G Mouillet","year":"2018","unstructured":"Mouillet G, Paillard M-J, Maurina T et al (2018) Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial. Trials 19:221. https:\/\/doi.org\/10.1186\/s13063-018-2613-8","journal-title":"Trials"},{"key":"4884_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/jcpt.13517","volume":"47","author":"T Ito","year":"2022","unstructured":"Ito T, Yamamoto K, Furukawa J et al (2022) Association of sunitinib concentration and clinical outcome in patients with metastatic renal cell carcinoma treated with a 2-week\u2010on and 1\u2010week\u2010off schedule. J Clin Pharm Ther 47:81\u201388. https:\/\/doi.org\/10.1111\/jcpt.13517","journal-title":"J Clin Pharm Ther"},{"key":"4884_CR33","doi-asserted-by":"publisher","unstructured":"Agarwal MA, Sridharan A, Pimentel RC, Markowitz SM, Rosenfeld LE, Fradley MG, Yang EH. Ventricular Arrhythmia in Cancer Patients: Mechanisms, Treatment Strategies and Future Avenues. Arrhythm Electrophysiol Rev. 2023 May 29;12:e16. https:\/\/doi.org\/10.15420\/aer.2023.04","DOI":"10.15420\/aer.2023.04"},{"key":"4884_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","volume":"66","author":"BE Houk","year":"2010","unstructured":"Houk BE, Bello CL, Poland B et al (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66:357\u2013371. https:\/\/doi.org\/10.1007\/s00280-009-1170-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"4884_CR35","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1021\/acs.chemrestox.8b00005","volume":"31","author":"GM Amaya","year":"2018","unstructured":"Amaya GM, Durandis R, Bourgeois DS et al (2018) Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib. Chem Res Toxicol 31:570\u2013584. https:\/\/doi.org\/10.1021\/acs.chemrestox.8b00005","journal-title":"Chem Res Toxicol"},{"key":"4884_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11096-016-0414-2","volume":"39","author":"E Vandael","year":"2017","unstructured":"Vandael E, Vandenberk B, Vandenberghe J et al (2017) Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm 39:16\u201325. https:\/\/doi.org\/10.1007\/s11096-016-0414-2","journal-title":"Int J Clin Pharm"},{"key":"4884_CR37","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.18203\/2349-3933.ijam20194202","volume":"6","author":"N AG","year":"2019","unstructured":"AG N, R. A (2019) Evaluation of the QTc internal and QT dispersion in patients with newly detected clinical hypothyroidism. Int J Adv Med 6:1416. https:\/\/doi.org\/10.18203\/2349-3933.ijam20194202","journal-title":"Int J Adv Med"},{"key":"4884_CR38","doi-asserted-by":"publisher","first-page":"300","DOI":"10.18203\/2349-3933.ijam20220434","volume":"9","author":"S Janakiraman","year":"2022","unstructured":"Janakiraman S, Arivazhagan RB, Chinnusamy M (2022) Prevalence of QTc prolongation among hypertensive patients and its association with other co-morbidities. Int J Adv Med 9:300. https:\/\/doi.org\/10.18203\/2349-3933.ijam20220434","journal-title":"Int J Adv Med"}],"updated-by":[{"DOI":"10.1007\/s00280-026-04945-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000}}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04884-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04884-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04884-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:47:42Z","timestamp":1789789662000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04884-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4884"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04884-y","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the given and family names of the authors","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00280-026-04945-2","URL":"https:\/\/doi.org\/10.1007\/s00280-026-04945-2","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Agata Sa\u0142ek-Za\u0144 obtained travel grants and lecture honoraria from Janssen-Cilag, Ipsen, Astra Zeneca, Pierre Fabre, BMS, MSD.Miros\u0142awa P\u00fcsk\u00fcll\u00fco\u011flu obtained travel grants and lecture honoraria from AstraZeneca, Roche, Novartis, Elli Lilly, Janssen, Gilead and Amgen.Aleksandra Grela-Wojewoda obtained travel grants and lecture honoraria from Roche, Novartis, Lili, Astellas, Pfizer, Amgen, Swixx, Pierre Fabre, Egis, BMS, MSD.Tomasz Bana\u015b, Justyna Jaworska, Agnieszka Pietruszka, Agnieszka St\u0105p\u00f3r, Maciej St\u0105p\u00f3r: declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"40"}}